SCHEMBL9984284

SCHEMBL9984284

Cc1cc2[nH]ccc2cc1Oc1cncnc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.43
TLR7 Q9NYK1 1/20 0.43
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
PRKCQ Q04759 2/20 0.35
PRKCD Q05655 1/20 0.35
GPR84 Q9NQS5 1/20 0.35
KDR P35968 1/20 0.34
FYN P06241 1/20 0.33
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
ERBB3 P21860 1/20 0.33
ERBB4 Q15303 1/20 0.33
IKBKB O14920 1/20 0.33
CHUK O15111 1/20 0.33
GRM1 Q13255 1/20 0.32
BRD4 O60885 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL187054 0.74 TLR8 (0.55) TLR8TLR7MEN1POLBMAPK1
SCHEMBL827047 0.69 GPR84 (0.54) MEN1POLBMAPK1KMT2AGPR84
SCHEMBL25991983 0.68 TLR8 (0.39) TLR8TLR7MEN1POLBMAPK1
SCHEMBL9413340 0.68 ACHE (0.47) TLR8TLR7MEN1POLBMAPK1
SCHEMBL187674 0.67 MEN1 (0.52) TLR8TLR7MEN1POLBMAPK1
SCHEMBL30354830 0.67 ALDH1A1 (0.41) MEN1POLBKMT2AEGFRERBB2
SCHEMBL5570133 0.67 ALDH1A1 (0.41) MEN1POLBKMT2AEGFRERBB2
SCHEMBL27606133 0.65 SMN1; SMN2 (0.52) MEN1MAPK1KMT2A
SCHEMBL186995 0.65 STAT3 (0.48) POLBMAPK1BRD4
Indole SCHEMBL5998581 0.65 TRPA1 (0.55) TLR8TLR7MEN1POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582668-B1 CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-01-13 EP disclosed
EP-2582668-B1 CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-01-13 EP disclosed
EP-2582668-A1 CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2013-04-24 EP disclosed
US-20130096118-A1 CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2013-04-18 US disclosed
US-20130096118-A1 CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2013-04-18 US disclosed
WO-2011159857-A1 CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-22 WO disclosed
WO-2011159857-A1 CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096118-A1 CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, PRKACA, CILK1 TLR8 1848/4885TLR7 1179/4885MEN1 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.